AXIM Biotechnologies, Inc. (NASDAQOTH:AXIM)

CAPS Rating: 1 out of 5


This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

4 Outperform
38 Underperform

All-Star Players

1 Outperform
28 Underperform

Wall Street

0 Outperform
0 Underperform

Top AXIM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

TSIF (99.97)
Submitted November 09, 2016

Jed71 wrote this one up. $190M market cap. 6 employees.Timing for them was great as Cannabis stocks soared pre-election, even the ones without a product or any expectations… More


AXIM Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about AXIM.


Member Avatar TerryHogan (99.97) Submitted: 9/28/2018 2:11:08 AM : Underperform Start Price: $1.87 AXIM Score: +41.00

Playing technical analysis for fun.


Member Avatar Bigsef77 (67.49) Submitted: 4/5/2018 3:16:36 PM : Outperform Start Price: $3.85 AXIM Score: -75.93

Better to be lucky than good & I got lucky.

AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
GlobeNewswire•April 3, 2018

NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Memo of Understanding (“MOU”) with a leading Korean specialty pharmaceutical company for the commercialization of two of the Company’s cannabinoid-based propriety pharmaceutical applications, CanChew+™ and MedChew®, in South Korea.

The MOU, which was reached on March 30, 2018, outlines how distribution partner will monitor the regulatory environment in the country and work with the South Korean Ministry of Food and Drug Safety (“MFDS”) in order to register the products for sale to the more than 50 million people in South Korea.

“Preparation for international market expansion is vital at this stage of our company’s growth,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “As the regulations and public perception of cannabinoid-based therapeutics shift toward acceptance throughout the world, AXIM will be ready to capture as much market share as possible for treatments of various indications. We have seen promising results in our initial studies that we hope to bring to a worldwide audience upon approval from regulatory officials.”

The Company’s flagship CanChew pharmaceutical program currently is currently undergoing human clinical trials for treatment of Irritable Bowel Syndrome (“IBS”). The MedChew program will feature products targeting treatment for pain and spasticity in Multiple Sclerosis patients as well as a bioequivalent product to Marinol using dronabinol for treatment of nausea associated with cancer treatment. Additional targeted indications for these programs include drug-related psychosis, Restless Leg Syndrome, Parkinson’s disease, and dementia,


Member Avatar TSIF (99.97) Submitted: 11/9/2016 1:21:11 PM : Underperform Start Price: $4.74 AXIM Score: +101.51

Jed71 wrote this one up.

OTC $190M market cap. 6 employees.
Timing for them was great as Cannabis stocks soared pre-election, even the ones without a product or any expectations to expand into new states.

.............."a biotechnology company, focuses on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products.....

Target sub $0.10


Find the members with the highest scoring picks in AXIM.

Score Leader


whatsthepoint (99.98) Score: +192.06

The Score Leader is the player with the highest score across all their picks in AXIM.

Member Name Member
Call Time
Score Commentary
tsperbeck 99.80 12/1/2016 Underperform 1Y $8.89 -90.10% +16.40% +106.50 0 Comment
germanjuggler 69.54 1/11/2017 8/7/2018 Underperform 1Y $11.90 -92.61% +12.81% +105.42 0 Comment
hesterprin 58.79 12/1/2016 11/9/2017 Underperform 1Y $8.50 -89.65% +15.69% +105.34 0 Comment
Doppelganger 40.26 1/10/2017 Underperform 5Y $11.40 -92.28% +12.87% +105.15 0 Comment
warrenout 99.50 11/22/2016 Underperform 5Y $8.00 -89.00% +15.80% +104.80 0 Comment
RES7 98.52 12/8/2016 Underperform 5Y $9.16 -90.39% +13.71% +104.10 0 Comment
Mikimikkers 98.49 11/18/2016 Underperform 1Y $6.85 -87.15% +16.57% +103.72 0 Comment
Dosada123 91.98 11/30/2016 Underperform 5Y $7.33 -87.99% +15.22% +103.21 0 Comment
patatepoil6 99.91 12/16/2016 Underperform 5Y $8.88 -90.08% +12.99% +103.07 0 Comment
gcaderas 79.44 4/18/2017 Underperform 5Y $13.20 -93.33% +9.26% +102.59 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AXIM.